Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors

被引:6
|
作者
Ruiz Castro, Beatriz Guerreiro [1 ]
Souza, Cristiano de Padua [2 ]
Mattos da Cunha Andrade, Carlos Eduardo [3 ]
Vieira, Marcelo de Andrade [3 ]
Pinto de Andrade, Diocesio Alves [4 ]
dos Reis, Ricardo [3 ]
机构
[1] Fac Ciencias Saude Barretos Dr Paulo Prata, Barretos, SP, Brazil
[2] Hosp Canc Barretos, Gynecol Clin Oncol Dept, Barretos, SP, Brazil
[3] Hosp Canc Barretos, Gynecol Oncol Dept, Barretos, SP, Brazil
[4] Inst Oncol Ribeirao Preto, InORP ONCOCLIN Grp, Ribeirao Preto, SP, Brazil
来源
REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA | 2019年 / 41卷 / 07期
关键词
ovarian neoplasms; Sertoli-Leydig cell tumor; oncologic prognosis; CORD-STROMAL TUMORS; CLINICOPATHOLOGICAL ANALYSIS; HYPERESTROGENISM; MANAGEMENT;
D O I
10.1055/s-0039-1693056
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Cancer de Barretos, Barretos, state of Sao Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presented with virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 UAL), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (beta-hCG) was 0.6 mUl/ml (0.0-2.3 mUl(ml), carcinoem-bryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopa-thological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation of Gynecology and Obstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of them underwent 3 cycles of paclitaxel and carboplatin every 21 days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred.
引用
收藏
页码:440 / 448
页数:9
相关论文
共 50 条
  • [1] Ovarian Sertoli-Leydig cell tumors with pseudoendometrioid tubules (pseudoendometrioid Sertoli-Leydig cell tumors)
    McCluggage, W. Glenn
    Young, Robert H.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007, 31 (04) : 592 - 597
  • [2] Ovarian Sertoli-Leydig cell tumors. A retrospective MITO study
    Sigismondi, Cristina
    Gadducci, Angiolo
    Lorusso, Domenica
    Candiani, Massimo
    Breda, Enrico
    Raspagliesi, Francesco
    Cormio, Gennaro
    Marinaccio, Marco
    Mangili, Giorgia
    GYNECOLOGIC ONCOLOGY, 2012, 125 (03) : 673 - 676
  • [3] Ovarian Sertoli-Leydig cell tumors: an analysis of 13 cases
    Guo, Ying
    Wang, Jing
    Li, Yuhong
    Wang, Yudong
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2020, 302 (01) : 203 - 208
  • [4] Pediatric ovarian Sertoli-Leydig cell tumors with heterologous rhabdomyosarcoma elements: Clinical case series and review of the literature
    Koo, Jane
    Garrington, Timothy P.
    Kerr, Karol
    Treece, Amy L.
    Cost, Carrye R.
    PEDIATRIC BLOOD & CANCER, 2020, 67 (10)
  • [5] Ovarian Sertoli-Leydig cell tumors: MRI findings and pathological correlation
    Cai, Song-Qi
    Zhao, Shu-Hui
    Qiang, Jin-Wei
    Zhang, Guo-Fu
    Wang, Xue-Zhen
    Wang, Li
    JOURNAL OF OVARIAN RESEARCH, 2013, 6
  • [6] A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors
    Gui, Ting
    Cao, Dongyan
    Shen, Keng
    Yang, Jiaxin
    Zhang, Yiwen
    Yu, Qi
    Wan, Xirun
    Xiang, Yang
    Xiao, Yu
    Guo, Lina
    GYNECOLOGIC ONCOLOGY, 2012, 127 (02) : 384 - 389
  • [7] Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors
    Demidow, V. N.
    Lipatenkova, J.
    Vikhareva, O.
    Van Holsbeke, C.
    Timmerman, D.
    Valentin, L.
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2008, 31 (01) : 85 - 91
  • [8] Ovarian Sertoli-Leydig cell tumours: A systematic review of relapsed cases
    Nef, James
    Huber, Daniela Emanuela
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2021, 263 : 261 - 274
  • [9] Sertoli-Leydig Cell Ovarian Tumors: Is Fertility or Endocrine-Sparing Surgery an Option upon Relapse?
    Seidler, Stephanie J.
    Huber, Alexandre
    Nef, James
    Huber, Daniela E.
    CASE REPORTS IN ONCOLOGY, 2020, 13 (02): : 935 - 940
  • [10] Pediatric Sertoli-Leydig Cell Tumors of the Ovary
    Yang, Bo
    Chour, William
    Salazar, Cristo Guardado
    Zamiara, Paul
    Schmidt, Ryan J.
    Raca, Gordana
    Shillingford, Nick
    Zhou, Shengmei
    Warren, Mikako
    Parham, David M.
    Pawel, Bruce
    Wang, Larry L.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2024, 48 (02) : 194 - 203